Merck KGaA Company Profile (NASDAQ:MKGAY)

About Merck KGaA

Merck KGaA logoMerck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company operates through four business segments: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnological origin. The Consumer Health division comprises the over-the-counter products for preventive health care and self-treatment of minor ailments. The Merck Serono and Consumer Health divisions form together the Company's Pharmaceutical business sector. The Merck Millipore division comprises the activities of the Millipore Corporation. The Performance Materials division consists mainly of the Liquid Crystals and Pigments & Cosmetics business units. The Company operates through numerous subsidiaries, including Peer+ BV, AZ Electronic Materials (AZ), BioControl Systems Inc and Ormet Circuits Inc., a material supplier for the semiconductor industry.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MKGAY
  • CUSIP:
Key Metrics:
  • Previous Close: $36.35
  • 50 Day Moving Average: $36.24
  • 200 Day Moving Average: $35.30
  • 52-Week Range: $1,307,021,000.00 - $27.44
  • Trailing P/E Ratio: 30.08
  • Foreward P/E Ratio: 5.24
  • P/E Growth: 2.26
  • Market Cap: $47.56B
  • Outstanding Shares: 1,307,021,000
Additional Links:
Companies Related to Merck KGaA:

Analyst Ratings

Consensus Ratings for Merck KGaA (NASDAQ:MKGAY) (?)
Ratings Breakdown: 4 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $65.00 (78.62% upside)

Analysts' Ratings History for Merck KGaA (NASDAQ:MKGAY)
DateFirmActionRatingPrice TargetDetails
10/14/2016Bank of America CorpUpgradeNeutral -> BuyView Rating Details
8/12/2016Berenberg BankDowngradeBuy -> HoldView Rating Details
8/10/2016Credit Suisse GroupUpgradeNeutral -> Outperform$73.00View Rating Details
8/10/2016Jefferies Group LLCReiterated RatingHold$53.00 -> $57.00View Rating Details
7/18/2016BMO Capital MarketsReiterated RatingMarket PerformView Rating Details
5/25/2016DZ Bank AGReiterated RatingBuyView Rating Details
5/19/2016J P Morgan Chase & CoReiterated RatingNeutralView Rating Details
5/17/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
4/8/2016Nord/LBReiterated RatingBuyView Rating Details
4/8/2016Deutsche Bank AGReiterated RatingBuyView Rating Details
2/6/2016Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$60.00 -> $56.00View Rating Details
12/1/2015Barclays PLCUpgradeEqual Weight -> Overweight$64.00 -> $66.00View Rating Details
11/17/2015ArgusReiterated RatingBuy$70.00 -> $65.00View Rating Details
10/26/2015Societe GeneraleReiterated RatingNeutralView Rating Details
7/2/2015Piper Jaffray CompaniesReiterated RatingUnderweightView Rating Details
6/25/2015HSBC Holdings plcInitiated CoverageHoldView Rating Details
4/29/2015BNP ParibasInitiated CoverageNeutralView Rating Details
(Data available from 2/26/2015 forward)


Earnings History for Merck KGaA (NASDAQ:MKGAY)
No earnings announcements for this company have been tracked by


Earnings Estimates for Merck KGaA (NASDAQ:MKGAY)
Current Year EPS Consensus Estimate: $6.71 EPS
Next Year EPS Consensus Estimate: $6.95 EPS


Dividend History for Merck KGaA (NASDAQ:MKGAY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Merck KGaA (NASDAQ:MKGAY)
No insider trades for this company have been tracked by


Latest Headlines for Merck KGaA (NASDAQ:MKGAY)
News Icon(MRK) Releases Earnings Results, Reports EPS of $0.89 EPS (NASDAQ:MKGAY) - February 2 at 7:23 PM
News IconThe Merck & Company, Inc. (MRK) Stake Increased by Barrett Asset Management LLC (NASDAQ:MKGAY) - January 29 at 4:42 AM logoMerck KGaA teams up with Domain Therapeutics in immuno-oncology (NASDAQ:MKGAY) - January 23 at 10:10 AM logoAstra's Mystic Mystery And Other Surprises In Store (NASDAQ:MKGAY) - January 18 at 7:05 PM logoMerck KGaA And Palantir Launch New Healthcare Acceleration Partnership (NASDAQ:MKGAY) - January 13 at 5:07 AM
News IconNext Weeks Broker Price Targets For Merck KGaA (MKGAY) (NASDAQ:MKGAY) - January 12 at 7:05 PM logoVertex to collaborate with Germany's Merck in oncology (NASDAQ:MKGAY) - January 12 at 12:10 AM logoGerman Merck Unveils Its Secret Weapon (NASDAQ:MKGAY) - January 10 at 7:27 PM logoMerck Acquires BioControl to Strengthen Position in Food Safety Testing (NASDAQ:MKGAY) - January 4 at 7:23 PM logoMerck KGaA Acquires BioControl Systems (NASDAQ:MKGAY) - January 4 at 7:23 PM logoETFs with exposure to Merck KGaA : December 22, 2016 (NASDAQ:MKGAY) - December 22 at 6:53 PM logoMetformin Products, including Glucophage® Approved for Type 2 Diabetes Patients with Moderate Renal Impairment in Europe (NASDAQ:MKGAY) - December 21 at 9:18 AM logoMerck and the European Space Agency Extend Collaboration to Foster Innovation, Digitalization (NASDAQ:MKGAY) - December 16 at 7:13 PM logoRoche Expands Distribution Agreement With Merck KgaA's Life Science Business (NASDAQ:MKGAY) - December 1 at 9:37 AM logoRoche expands distribution partnership with Merck KGaA (NASDAQ:MKGAY) - December 1 at 9:37 AM logoEvotec and Merck KGaA team up to discover new therapeutic targets (NASDAQ:MKGAY) - November 30 at 11:21 AM logo8:19 am Merck KGaA and Pfizer (PFE (NASDAQ:MKGAY) - November 29 at 2:51 PM logoFDA accepts avelumab BLA under Priority Review for rare type of skin cancer (NASDAQ:MKGAY) - November 29 at 2:51 PM logoFrosty-brilliant Silver Shine: The Merck Pigment Innovation Ronastar® Frozen Jewel (NASDAQ:MKGAY) - November 22 at 6:20 PM logoQuintilesIMS forms collaboration with major drug firms to better understand real-world uses of cancer treatments (NASDAQ:MKGAY) - November 22 at 10:21 AM logoBRIEF-QuintilesIMS forms new Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to generate real world insights on usage of anti-cancer therapies across Europe (NASDAQ:MKGAY) - November 22 at 8:23 AM logoGermany's Merck Lifts Full Year Guidance After Sigma-Aldrich Boosts Sales (NASDAQ:MKGAY) - November 16 at 9:51 AM logoMerck Raises Profit Forecast for 2016 Following Good Third Quarter (NASDAQ:MKGAY) - November 16 at 9:51 AM
News IconGermany's Merck Raises Guidance on Life Science, Health Care Growth--Update (NASDAQ:MKGAY) - November 15 at 9:52 AM logoMerck KgaA Lifts FY16 Earnings View As Q3 Results Climb, Stock Up (NASDAQ:MKGAY) - November 15 at 9:52 AM logoMerck KGaA, Darmstadt, Germany's Phase IIb ADDRESS II Results Confirm Potential of Atacicept as a Candidate Therapy for SLE (NASDAQ:MKGAY) - November 14 at 10:18 AM logo8:01 am Merck KGaA announces the results of the ADDRESS II Phase IIb, multicenter study on atacicept in patients with systemic lupus erythematosus; primary endpoint not met in overall study population (NASDAQ:MKGAY) - November 14 at 10:18 AM logoMerck KGaA, Darmstadt, Germany, Presents Phase II Data on the Safety and Efficacy of Atacicept at the 2016 ACR/ARHP Annual Meeting (NASDAQ:MKGAY) - November 2 at 9:42 AM logoMerck KGaA, Darmstadt, Germany Partners with American Cancer Society to Address Cancer in Women (NASDAQ:MKGAY) - November 1 at 6:27 PM logoTransgene Pins Hopes On Cancer Vaccine Combos (NASDAQ:MKGAY) - October 14 at 5:58 PM logoMerck Introduces First Certified Spiking Solution® of Heavy Labeled Thyroglobulin Protein (NASDAQ:MKGAY) - October 13 at 6:15 PM logoMerck KgaA To Meet 2018 Targets; Sees EUR 4 Bln Sales From New Products By 2022 (NASDAQ:MKGAY) - October 13 at 9:44 AM logoMilliporeSigma Launches Viresolve® Pro Shield H for More Robust, Economical Parvovirus Removal (NASDAQ:MKGAY) - September 26 at 6:08 PM logoMerck KGaA Invests Over €50 Mln In Pharma Packaging Building In Darmstadt (NASDAQ:MKGAY) - September 21 at 10:17 AM logoMerck Lab Earns ISO Accreditation for Quality Control of Culture Media (NASDAQ:MKGAY) - September 14 at 10:26 AM logoETF’s with exposure to Merck KGaA : August 31, 2016 (NASDAQ:MKGAY) - September 1 at 9:17 AM


What is Merck KGaA's stock symbol?

Merck KGaA trades on the NASDAQ under the ticker symbol "MKGAY."

Where is Merck KGaA's stock going? Where will Merck KGaA's stock price be in 2017?

10 brokerages have issued 12 month target prices for Merck KGaA's shares. Their forecasts range from $57.00 to $73.00. On average, they expect Merck KGaA's stock price to reach $65.00 in the next twelve months.

How do I buy Merck KGaA stock?

Shares of Merck KGaA can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Merck KGaA stock cost?

One share of Merck KGaA stock can currently be purchased for approximately $36.39.

Merck KGaA (NASDAQ:MKGAY) Chart for Sunday, February, 26, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Merck KGaA (NASDAQ:MKGAY)

Earnings History Chart

Earnings by Quarter for Merck KGaA (NASDAQ:MKGAY)

Dividend History Chart

Dividend Payments by Quarter for Merck KGaA (NASDAQ:MKGAY)

Last Updated on 2/26/2017 by Staff